Aberrant activation of Wingless-type (Wnt)/b-catenin signaling is widespread in human cervical cancer. However, the underlying mechanisms of Wnt activation and the therapeutic potential of Wnt inhibition remain largely unknown. Here, we demonstrate that the Wnt inhibitory factor 1 (WIF1), a secreted Wnt antagonist, is downregulated in all human primary cervical tumors and cell lines analyzed. Our data reveal that WIF1 downregulation occurs due to promoter hypermethylation and is an early event in cervical oncogenesis. WIF1 re-expression upon 5-aza-2 0 -deoxycytidine treatment or WIF1 gene transfer induces significant apoptosis and G 2 /M arrest, and inhibits cervical cancer cell proliferation in vitro. Consistent with this, treatment of established mice tumor xenografts with peritumoral WIF1 gene transfer results in a significant inhibition of cancer growth and invasion. WIF1 treatment causes a significant decrease in intracellular WNT1 and TCF-4 proteins revealing novel Wnt-regulatory mechanisms. Thus, WIF1 causes a major cellular re-distribution of b-catenin and a significant inhibition of the Wnt/b-catenin pathway in tumor cells, as documented by a remarkable reversion in the expression of Wnt/b-catenin transcriptional target genes (E-cadherin, c-Myc, cyclin D1, CD44 and VEGF). Consequently, multiple critical events in tumor progression and metastasis such as cell proliferation, angiogenesis and invasion were inhibited by WIF1. In addition, WIF1 modulated the expression of specific anti-apoptotic and apoptotic proteins, thereby inducing significant apoptosis in vivo. Our findings demonstrate for the first time that WIF1 downregulation by epigenetic gene silencing is an important mechanism of Wnt activation in cervical oncogenesis. Of major clinical relevance, we show that peritumoral WIF1 gene transfer reduces not only cancer growth but also invasion in well-established tumors. Therefore, our data provide novel mechanistic insights into the role of WIF1 in cervical cancer progression, and the important preclinical validation of WIF1 as a potent drug target in cervical cancer treatment.
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Introduction
Cervical cancer is the second most common cause of cancer deaths in women worldwide accounting for nearly 300 000 deaths annually (Parkin and Bray, 2006) . Epidemiological and laboratory-based studies have identified infection with human papillomavirus (HPV) as the first hit in cervical cancer development (Woodman et al., 2007) . In addition, it was hypothesized that activation of the Wingless-type (Wnt)/b-catenin pathway is the second hit in the multistep process of cervical oncogenesis (Uren et al., 2005; Perez-Plasencia et al., 2008) , but the precise molecular mechanisms of cervical cancer progression remain unclear.
The Wnt signaling pathway is a major regulator of cell proliferation, migration and differentiation, controlling embryogenesis, adult tissue homeostasis and tumor progression (MacDonald et al., 2009) . The binding of a specific Wnt to a receptor complex comprised of Frizzled/low-density lipoprotein receptor-related protein (Fz/LRP) or to distinct receptors leads to either b-catenindependent or b-catenin-independent signaling pathways. The former culminates in the stabilization of b-catenin and the latter uses a multitude of distinct downstream effectors. In the Wnt/b-catenin pathway, the binding of Wnts to the Fz receptors stabilizes b-catenin and prevents its phosphorylation and proteosomal degradation. Stabilized b-catenin translocates to the nucleus where it interacts with T-cell factor/lymphoid enhancer factor (TCF/LEF) to activate transcription. Interaction of Wnt ligands with their receptors is enhanced by heparin sulfate glycosaminoglycans controlling Wnt diffusion at the cell surface (Mikels and Nusse, 2006) or inhibited through diverse mechanisms by several secreted antagonists (Kawano and Kypta, 2003) . Members of the Dickkopf family of Wnt antagonists bind to LRP5/6 causing disruption of the Wnt/Fz/LRP complex (MacDonald et al., 2009) . Members of the secreted Frizzled-related proteins antagonize Wnt/b-catenin signaling by forming complexes with the Fz receptors or by sequestering Wnts (Bovolenta et al., 2008) . The Wnt inhibitory factor 1 (WIF1) binds directly to extracellular Wnt ligands, preventing their interaction with the receptors and leading to b-catenin degradation (Hsieh et al., 1999) .
Aberrant activation of the Wnt/b-catenin signaling pathway contributes to the progression of several major human cancers (MacDonald et al., 2009) . Therefore, inhibition of Wnt effects has major therapeutic potential. Cytoplasmic and nuclear accumulation of b-catenin is the main hallmark of Wnt activation and is present in 470% of cervical cancer specimens (Shinohara et al., 2001) . However, mutations of APC and b-catenin genes that are usually responsible for the deregulated Wnt/bcatenin pathway in other tumors (such as colon and liver cancers) are rare in human cervical cancer (Shinohara et al., 2001; Ueda et al., 2001) . These data suggest that Wnt activation in cervical cancer occurs mainly upstream of b-catenin. Supporting this hypothesis, recently, promoter hypermethylation of Wnt antagonists Dickkopf-3, secreted Frizzled-related protein-1, secreted Frizzled-related protein-2 and secreted Frizzled-related protein-4 has been identified in cervical carcinoma (Chung et al., 2009; Lee et al., 2009) . However, the precise role of WIF1 in cervical cancer progression and treatment is yet to be determined.
Here, we demonstrate for the first time that epigenetic silencing of the WIF1 gene is a frequent event in cervical oncogenesis. In vitro WIF1 restoration significantly blocks cell-cycle progression and induces apoptosis. In vivo studies reveal novel mechanisms by which WIF1 expression causes a dramatic reversion of the Wnt/ b-catenin target gene expression and demonstrate that WIF1 significantly reduces cervical tumor growth by inducing massive apoptosis and inhibiting tumor proliferation, invasion and angiogenesis. Of major clinical importance, our in vivo results show that WIF1 inhibits the growth of well-established cervical tumor xenografts and therefore, may serve as a potent therapeutic agent in cervical cancer treatment.
Results

WIF1 downregulation is frequent and occurs early in human cervical cancer
We first examined WIF1 expression by immunohistochemistry in a cervical cancer tissue array. In the noncancerous epithelium, WIF1 expression was observed as a moderate or strong cytoplasmic brown staining (Figure 1 ). This cytoplasmic pattern is consistent with a previous report (Wissmann et al., 2003) . WIF1 expression was low or undetectable in all tissue array cancer samples ( Figure 1a) . We then evaluated WIF1 expression in a series of cervical tissue samples collected in our institution. All 21 normal cervical samples obtained from women undergoing surgery for non-cancerous diagnosis expressed high WIF1 levels (Figure 1b) . In contrast, WIF1 expression was undetectable in 12 of 16 cervical carcinoma samples (Figure 1b) . The remaining four cervical cancer samples had detectable, but very low levels of WIF1 expression. By comparison with the normal cervical epithelium, cancer samples showed a significant decrease in WIF1 expression (Figure 1c) . Seven of the 16 cancer samples included adjacent histologically normal (4 cases) or dysplastic (3 cases) epithelium. The expression of WIF1 in the matched adjacent epithelium was significantly higher than in the corresponding malignant tissue, but significantly lower than in the normal cervical epithelium obtained from women without cancer ( Figure 1c ). In addition, we quantified WIF1 mRNA expression in normal and cervical cancer tissues by real-time reverse transcriptase-PCR analysis. Our data clearly demonstrate a significant decrease in WIF1 mRNA expression ( Figure 1d ) and correlate well with protein expression levels as shown by immunohistochemistry (Figures 1a-c) in cervical cancer when compared with the normal tissue. These data show that WIF1 downregulation is widespread in cervical cancer and an early event in cervical cancer progression.
WIF1 is downregulated in human cervical cancer due to promoter hypermethylation Epigenetic silencing of secreted Wnt antagonists has an important role in Wnt activation (MacDonald et al., 2009) . We performed WIF1 promoter methylationspecific PCR in normal and cancer cervical samples. No WIF1 promoter methylation was observed in the 21 normal epithelial cervical samples analyzed. Therefore, all normal samples were found to be unmethylated (0% methylation) (Figure 2a ). In contrast, the WIF1 promoter was methylated in 14 out of 16 primary cervical cancer samples (87.5% methylation) (Figure 2a ). In some cancer samples, but not in the normal epithelium, we observed the presence of both methylated and unmethylated bands (Figure 2a ). Bisulfite-sequencing analysis of the WIF1 promoter in normal samples confirmed the unmethylated WIF1 status (Figure 2b ). On average, only 1 methylated CpG site (range 0-5) was observed per normal sample. In contrast, in cancer samples (Figure 2b ), we observed an average of 19 methylated CpG sites (range 3-40) per sample (Po0.0001). In several tumors, we observed the co-existence of WIF1 alleles densely methylated (exclusively present in cancer samples) with unmethylated alleles (pattern similar to normal tissue). This is consistent with WIF1 promoter methylation-specific PCR results and might reflect a mix of tumor and peritumoral normal tissue in our samples. Alternatively, the WIF1 promoter might not be completely methylated in some tumors. These results clearly demonstrate that WIF1 promoter methylation is a widespread event in cervical cancer. Consistent with our observation in primary tumors, all three cervical cancer cell lines studied showed strong promoter methylation (Supplementary Figure 1 ). Accordingly, treatment of HeLa, CC1 and C33A cells with 5-aza-2 0 -deoxycytidine (DAC) caused a significant increase in WIF1 mRNA expression, as assessed by real-time reverse transcriptase-PCR (Supplementary Figure 2a) . Taken together, these data demonstrate that WIF1 is frequently downregulated through promoter hypermethylation in cervical cancer. Figure 2c ). Therefore, we used these cells to determine whether the alterations observed with DAC treatment resulted specifically from induction of WIF1 expression. Cells were transiently transfected with empty vector or pCI-blast-WIF1, which expresses full-length WIF1 protein, and assessed for cell proliferation, cellcycle progression and apoptosis. Re-expression of WIF1 resulted in a significant reduction in the total number of viable cells at all time points (Figure 3a) , indicating the potent growth-inhibitory effects of WIF1. In bladder carcinoma and osteosarcoma cell lines, WIF1 has been reported to induce G 1 arrest and growth inhibition (Kansara et al., 2009; Tang et al., 2009) . However, consistent with the G 2 /M arrest observed in cervical cancer cells after DAC treatment, we observed a significant increase in the G 2 /M phase of the cell cycle in WIF1-transfected cells (Figure 3b ), suggesting a cellspecific role for WIF1. In addition, WIF1 expression induced significant apoptosis ( Figure 3c ). Caspases have a major role in regulating apoptotic cell death (Li and Yuan, 2008) , and we observed a significant increase in caspase-3/7 activity after WIF1 transfection (Figure 3d ). 
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These data suggest that WIF1-induced apoptosis is mediated through caspase-3/7 activation. Taken together, these findings show that the results observed with DAC treatment are attributable to the induction of WIF1 and strongly suggest that WIF1 reduces cervical cancer cell proliferation by inducing G 2 /M arrest and apoptosis.
WIF1 inhibits cervical tumor growth in vivo Stably transfected WIF1 tumor cells have been used to study WIF1 biological function and to establish mice tumor xenograft models (Kawakami et al., 2009; Tang et al., 2009) . These models have shown a slower tumor growth rate for WIF1-expressing cells. However, from a clinical perspective, the therapeutic potential of WIF1 and its underlying cancer-inhibitory mechanisms are best determined in animal models with previously established tumors, as only these conditions mimic patients at the time of cancer diagnosis. To accomplish this, cervical tumor xenografts were generated, and weekly treatment with peritumoral injections of either empty vector or pCI-blast-WIF1 was initiated only when tumors reached 100-200 mm 3 . Importantly, WIF1 treatment dramatically reduced tumor volume (Po0.001) compared with vector treatment (Figures  4a-c) . In addition, we observed a significant decrease in tumor weight with WIF1 treatment compared with vector ( Figure 4d ). Overall, these results demonstrate that WIF1 treatment significantly reduce cervical tumor growth in well-established xenograft tumors and pinpoint its potential for the treatment of cervical cancer patients.
No significant difference in the overall body weight (Supplementary Figure 3) or behavior was observed in 
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I Ramachandran et al treated mice. Autopsies revealed no macroscopic or microscopic lesions or anomalies in any of the several tissues processed (data not shown). These results indicate the absence of significant systemic or local toxicity associated with WIF1 treatment.
WIF1 inhibits tumor proliferation and invasion
To investigate the mechanisms of anti-tumor activity by WIF1, we sampled tumor tissues from xenografts. Interestingly, microscopic analysis of hematoxylin and eosin-stained sections revealed that 7 weeks of WIF1 treatment caused a significant decrease (Po0.0001) in mitotic cell numbers compared with vector (Supplementary Figure 4a ). Supporting these data, we also observed by immunofluorescence a marked decrease in the number of cells positive for phospho-Histone H3, a mitosis specific marker, in WIF1-treated tumors (Supplementary Figure 4b) . Remarkably, the microscopic analysis of hematoxylin and eosin-stained sections revealed a strong inhibition of tumor invasion by WIF1 (Figure 4e ). Vector-treated tumors were highly infiltrative, showing diffuse infiltration with single cell isolation. In patients, this 'spraylike' pattern is associated with advanced tumor stages, increased rate of recurrence and a reduced overall survival (Horn et al., 2006) . In contrast, WIF1-treated tumors presented with well-defined cohesive or 'pushing' borders, a pattern associated with a very good prognostic outcome (Horn et al., 2006) . Overall, these data demonstrate that WIF1 reduces tumor cell proliferation and invasion in vivo. Figure 6b) , and led to a remarkable cellular re-distribution of b-catenin (Figure 5b) .
Nuclear b-catenin interacts with TCF/LEF to activate gene transcription (Nusse, 2005) . We observed a significant decrease in TCF-4 mRNA (Supplementary Figure 5c ) and protein ( Figure 5c ) levels with WIF1 treatment. While vector-treated cells showed strong nuclear and cytoplasmic TCF-4 staining, TCF-4 expression was undetectable with WIF1 treatment (Figure 5c ). Supporting our in vivo results, treatment of cervical cancer cells with DAC in vitro led to a drastic decrease in TCF-4 protein expression as determined by western blot analysis (Supplementary Figure 5e) . Our results 
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for the first time show that TCF-4 is a transcriptional Wnt/b-catenin target and reveal a novel Wnt-regulatory loop by which WIF1 induces a strong Wnt pathway inhibition. c-Myc seems to be essential for sustaining proliferation of human tumor cells (Wang et al., 2007) . Vectortreated tumors showed very strong c-Myc nuclear immunostaining. Importantly, WIF1 treatment resulted in a marked downregulation of c-Myc, with tumor cells showing weak or no nuclear staining ( Supplementary  Figure 7a) . Consistent with c-Myc being a direct transcriptional Wnt/b-catenin target, the downregulation of c-Myc protein levels was concomitant with a significant decrease in c-Myc mRNA levels (Supplementary Figure 5d ). The expressions of cyclin D1 and CD44, other direct transcriptional Wnt/b-catenin targets with major roles in cell proliferation (Kainz et al., 1995; Fu et al., 2004) , were also markedly downregulated by WIF1 treatment (Supplementary Figures 7b and c) .
Tumor invasion into surrounding tissues requires epithelial cells to lose their polarity and intercellular adhesion (Polyak and Weinberg, 2009 ). E-cadherin is the prime mediator of intercellular adhesion (Huber and Weis, 2001 ) and its loss/downregulation is an hallmark of tumor invasion (Laux et al., 2004) . In vector-treated tumors, cells showed weak or loss of membranous Ecadherin expression and weak-to-moderate cytoplasmic staining (Figure 5d ). Importantly, WIF1 treatment resulted in a marked increase in the expression of Ecadherin (Figure 5d ), a direct b-catenin transcriptional target (Jamora et al., 2003) . Furthermore, in WIF1-treated tumors, E-cadherin staining was mainly localized to the cell membrane (Figure 5d ), a pattern commonly seen in the normal cervical epithelium. Overall, these results suggest that WIF1 inhibits human cervical cancer proliferation and invasion by having a major regulatory role on the expression of specific bcatenin direct transcriptional targets.
WIF1 downregulates WNT1 and VEGF and inhibits angiogenesis
Angiogenesis is a complex, multistep process that is involved in the progression and prognosis of several types of cancer, including cervical cancer (Phoophitphong et al., 2007) . To investigate whether WIF1 inhibits tumor angiogenesis, we performed immunostaining for CD31, an endothelial cell adhesion molecule, and measured the intratumor microvessel density. Tumors treated with WIF1 demonstrated a marked decrease in CD31 protein (Figure 6a ) and a significant decrease in the number of vessels per microscopic field when compared with vector ( Figure 6d) . WNT1, one of the Wnt ligands inhibited by extracellular WIF1 binding, has been shown to stimulate the proliferation of human endothelial cells (Wright et al., 1999) . In xenograft tumors treated with vector, WNT1 was observed as a moderate or strong cytoplasmic brown staining (Figure 6b ). However, WNT1 staining was absent in WIF1-treated tumors (Figure 6b ). Interestingly, there was no significant change in the mRNA level of WNT1 (data not shown), suggesting that the observed alterations result from changes at the protein level rather than at the transcriptional level. As WIF1 interaction with WNT1 occurs at the extracellular compartment, these data show yet another previously unknown level of Wnt regulation by WIF1 and suggest that WIF1 not only binds WNT1 protein and prevents Wnt activation but might also regulate WNT1 stability, cellular traffic and/or the level of WNT1 mRNA translation.
b-Catenin has been shown to regulate vascular patterning and promote angiogenesis by increasing vascular endothelial growth factor (VEGF) expression (Skurk et al., 2005) . Consistent with the potent role of WIF1 as a Wnt/b-catenin inhibitor, WIF1 treatment drastically decreased the expression of VEGF (Figure 6c ). Taken together, these data suggest that WNT1 and VEGF downregulation contribute to the potent anti-angiogenic effects of WIF1 in cervical cancer. Figure 8b) . No increase in the apoptotic index was observed in other tissues (data not shown).
In contrast to most human tumors, the majority of malignant cervical cancer cells, including HeLa cells, contain wild-type p53 (Johnson et al., 2002) , a major regulator of apoptosis. However, the expression of the HPV E6 protein results in degradation of the p53 protein and consequently the basal level of p53 expression is very low in cervical cancer cells (Johnson et al., 2002) . In agreement with this, we observed no p53 staining in vector-treated tumors (Figure 7a ). However, we observed a strong nuclear p53 staining in WIF1-treated tumors (Figure 7a ), suggesting that WIF1 might reduce E6 transcription, increase p53 transcription and/or prevent p53 degradation by HPV18/E6 oncoprotein. We also observed a marked increase in the expression of cytoplasmic and nuclear p21 (Figure 7b ), a direct transcriptional target of p53 (Zuckerman et al., 2009) . p53 has been shown to directly and indirectly regulate the activity of the Bcl-2 family proteins (Hemann and Lowe, 2006) . In addition, p53 can act to repress Bcl-2 transcription (Hemann and Lowe, 2006) . In our study, the increase in p53 was not associated with a quantitative change in Bax expression (Figure 7d ), but was associated with a marked decrease in the expression of Bcl-2 (Figure 7d ) and increase in the expression of the effector caspase-3 (Figure 7c ). Taken together, both our in vitro and in vivo data indicate that WIF1 induces apoptosis primarily by decreasing the expression of anti-apoptotic protein Bcl-2 and increasing the effector caspases.
Discussion
Autocrine Wnt signaling and downregulation of extracellular antagonists cause constitutive Wnt/b-catenin activation in many human cancers and contribute to tumor progression (MacDonald et al., 2009) . The extracellular localization of these regulatory Wnt proteins, as well as their temporally restricted, highly localized and tissue-specific expression, makes them attractive molecular targets for cancer therapies.
WIF1 is a secreted Wnt antagonist that is often downregulated because of genomic rearrangement, genomic loss or promoter hypermethylation in several human tumors, including colon, lung, breast, prostate, bladder, kidney and salivary gland (Wissmann et al., 2003; Byun et al., 2005; Taniguchi et al., 2005; Ai et al., 2006; Urakami et al., 2006; Queimado et al., 2008; Kawakami et al., 2009) . Our study demonstrates that WIF1 downregulation is an early and widespread event in human cervical oncogenesis, which occurs frequently due to promoter hypermethylation. In agreement with the accepted knowledge that virtually all cervical cancer samples are positive for HPV, all cancer samples tested for HPV and included in our study were HPV positive. 
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The only 2 cancer samples, out of 16, for which we did not observe WIF1 promoter hypermethylation were positive for 'high-risk' HPV types (HPV16 and HPV18). Therefore, it is not possible to clearly establish a correlation between HPV and WIF1 methylation in primary tissue samples. Nonetheless, we observed that the CpG islands of the WIF1 promoter are more frequently methylated in HPV-positive HeLa and CC1 cells than in HPV-negative C33A cells. Although, the absolute significance of this observed correlation to HPV and WIF1 promoter hypermethylation is not known, it is important to note that HPV16/E7 has been shown to bind DNA methyl transferase enzyme (DNMT1) (Robertson, 2001 ), the enzyme responsible to add methyl groups in CpG islands, and increase its activity. Thus, in this context, our data support the hypothesis that HPV infection might favor methylation of the WIF1 promoter and contribute to the observed activation of the Wnt/bcatenin signaling pathway in cervical oncogenesis.
Our in vitro studies demonstrated that WIF1 reexpression induces G 2 /M arrest and apoptosis, and thereby inhibits cervical cancer cell proliferation. This inhibition of cell proliferation is consistent with the in vitro inhibition of cell growth by WIF1 as previously shown for other cancer cell lines (Ai et al., 2006; Kim et al., 2007; Kansara et al., 2009; Kawakami et al., 2009; Tang et al., 2009 ). However, in previous studies, WIF1 overexpression was shown to induce G 1 arrest in HPVimmortalized osteoblasts and osteosarcoma cell lines containing null or wild-type p53 (Kansara et al., 2009) , as well as in bladder cancer cell lines containing mutant p53 (Tang et al., 2009) . In contrast, our data show that in cervical cancer cells, which express very low levels of wild-type p53, WIF1 re-expression led to a significant increase in p53 expression, and induced cell-cycle arrest at G 2 /M and extensive apoptosis. The observed variation in the cell-cycle arrest, in the above studies when using different tumor cell lines, can be reconciled by the WIF1 inhibits cervical cancer growth and invasion I Ramachandran et al fact that p53 can regulate both G 1 and G 2 /M checkpoints (Agarwal et al., 1995) . However, the link between p53 status, diverse Wnt expression patterns and the contribution of cell or tissue context that could determine the specific mechanisms involved in the induction of growth arrest and apoptosis by WIF1, in specific human cancers, remain to be determined.
Consistent with our in vitro data, we observed that in our in vivo mice xenograft studies, treatment of wellestablished tumors with peritumoral WIF1 gene transfer resulted in a significant inhibition of cancer growth and invasion. Other in vivo studies have also evaluated the growth-inhibitory role of WIF1 in melanoma, lung, bladder, renal and prostate cancers (Kim et al., 2007; Lin et al., 2007; Kawakami et al., 2009; Tang et al., 2009; Yee et al., 2010) . Most of these studies used tumor cells stably expressing the WIF1 transgene to show that WIF1 overexpression significantly attenuates tumor growth in mouse models. Thus, like ours, these interesting studies, clearly demonstrate that WIF1 is a potent tumor suppressor. However, most excitingly, we demonstrate that the suppression of tumor progression upon WIF1 treatment is a result of synergistic convergence of multiple regulatory pathways, including induction of massive apoptosis and a significant decrease in proliferation, invasion and angiogenesis. Particularly, we report our novel observations that, in vivo, WIF1 induces a striking increase in tumor cell apoptosis, which seems to be a major contributor for the significant reduction in cervical cancer growth, and a major increase in membranous E-cadherin, which associates with a dramatic change in the pattern of cervical cancer invasion. Furthermore, of major clinical relevance, our in vivo mouse model most closely mimics the clinical settings wherein after a patient is diagnosed with cervical cancer, the patient subsequently undergoes drug therapy or treatment. Thus, in this clinically relevant setting, our results clearly demonstrate that in wellestablished tumors, weekly peritumoral WIF1 gene transfer significantly reduces not only xenograft cervical cancer growth but also tumor invasion.
We did not observe any major macroscopic or microscopic systemic side effects with WIF1 treatment in vivo. These results are consistent with the in vitro observations that WIF1 overexpression does not interfere with normal cell growth of primary osteoblasts (Kansara et al., 2009 ) and HEK293 cells (data not published). Moreover, the use of peritumoral injection has the selective advantage of treating tumors with WIF1 at the tumor site, while avoiding the potential side effects at undesired target tissues often associated with systemic therapeutic strategies.
Aberrant activation of the Wnt signaling pathway in our cervical cancer xenograft model is characterized by high expression levels of b-catenin (hallmark of Wnt activation), WNT1, TCF-4 and Wnt target genes. The overexpression of c-Myc, cyclin D1 and CD44 has been shown to promote tumor cell proliferation (Abbasi et al., 1993; Wielenga et al., 1999; Fu et al., 2004; Wang et al., 2007; Orian-Rousseau, 2010) and to associate with poor cervical cancer prognosis (Kainz et al., 1995; Speiser et al., 1997; Bae et al., 2001; Vijayalakshmi et al., 2002; Lu et al., 2005; Orian-Rousseau, 2010) . Importantly, WIF1-treated tumors demonstrated a marked decrease in the expression of b-catenin, TCF-4, c-Myc, cyclin D1 and CD44, with a consequent significant decrease in the tumor mitotic index. These data show that WIF1 treatment blocks Wnt/bcatenin pathway and inhibits cervical cancer cell proliferation. Furthermore, and most importantly, it suggests that re-expression of WIF1 in human cervical tumors might have major prognostic implications.
Downregulation of E-cadherin expression leads to the loss of intercellular adhesion and is a hallmark of tumor invasion (Laux et al., 2004) . Xenograft tumors treated with empty vector express very low levels of E-cadherin and presented with highly invasive borders. However, WIF1 treatment led to a marked increase in membranous E-cadherin and b-catenin, and to a dramatic change in tumor border configuration, from highly 'diffuse' infiltrative to a cohesive 'pushing' border. E-cadherin binds directly to b-catenin (Huber and Weis, 2001 ) and this binding is essential for formation of cellcell adhesion, which prevents tumor invasion (Laux et al., 2004) . Concurring with this, E-cadherin expression correlates negatively with progression of cervical intraepithelial neoplasia (Branca et al., 2006) . Overall, these data together with previous observations that cervical tumors with a 'diffuse' invasive pattern are associated with a significant decrease in survival rates as compared with tumors with a more cohesive or 'pushing' pattern of invasion (Horn et al., 2006) , strongly support the hypothesis that WIF1 blocks human cervical cancer progression, and its re-expression has the potential to change patient's prognosis.
In our mouse model, WIF1 treatment led to a significant reduction in the number of tumor microvessels. Several factors might contribute to this clinically relevant anti-angiogenic role of WIF1 such as: (1) a decrease in VEGF transcription caused by a decrease in nuclear b-catenin, a known promoter of angiogenesis by an increase in VEGF expression (Skurk et al., 2005) ; (2) a decrease in VEGF half-life because of a decrease in CD44, a well-established proteolysis inhibitor of VEGF (Jones et al., 2000) ; (3) an increase in p53 expression, as the loss of p53 has been correlated with an increased VEGF expression and tumor angiogenesis (Linderholm et al., 2001) ; (4) a decrease in WNT1, a protein shown to stimulate the proliferation and angiogenic functions of human endothelial cells (Wright et al., 1999; Gherghe et al., 2011) ; and (5) a decrease in the endothelial cell-cell adhesion molecule CD31, a protein required for neovascularization (DeLisser et al., 1997) . In early-stage cervical cancer, CD31 expression is significantly associated with lymphatic vascular space invasion and tumor size (Silva-Filho et al., 2006) . Similarly, serum VEGF-C upregulation seems to be a unique marker for an early diagnosis of cervical cancer metastasis (Mathur et al., 2005) . Overall, these data clearly demonstrate the important anti-angiogenic effects of WIF1 in cervical cancer xenograft mouse model and suggest that WIF1 treatment has the potential to prevent or reduce tumor progression.
